Cannabis and Pain: What People Report, What the Research Shows, and Where a Measured Dose Fits
Oct 12, 2026
Pain is the single most common reason people give for using medical cannabis. It is also one of the most oversold. Between marketing that promises relief and headlines that dismiss it entirely, it is hard to find a plain account of what is actually known.
So this post is not a recommendation. The DART does not advocate using cannabis to treat pain, and nothing here is medical advice. What follows is a sourced look at three separate things that often get blurred together: what people report doing, what controlled research has found, and what physician groups currently advise. At the end, we explain where a measured dry herb system fits for adults who have already made their own informed choice.
What people report
The survey data is consistent: pain comes up again and again.
- It is the top qualifying condition. An analysis of state medical cannabis registries across 20 states and Washington, D.C., published in Health Affairs, found chronic pain accounted for 62.2% of all patient-reported qualifying conditions, making it the most common by a wide margin.
- It is a leading reason among older adults. In the University of Michigan's 2024 National Poll on Healthy Aging, 63% of adults 50 and older who used cannabis said they did so to help with pain, behind only relaxation (81%) and sleep (68%).
- It shows up in small-dose use too. A 2026 national survey in the American Journal of Preventive Medicine found about 9.4% of U.S. adults have microdosed cannabis, and managing chronic pain was among the most commonly reported reasons, alongside anxiety and depression.
People are clearly reaching for cannabis with pain in mind. Whether it works, and for whom, is a different question.
What the research shows
Here is where the picture gets more modest, and more interesting.
The large reviews find small, short-term effects
The most comprehensive recent analysis, an updated systematic review in Annals of Internal Medicine, pooled 25 randomized trials with 2,303 participants, most with nerve-related (neuropathic) pain, lasting one to six months. Its findings:
- Oral THC-only products may slightly reduce pain, by under one point on a 0 to 10 scale (low-certainty evidence).
- Mouth sprays with roughly equal THC and CBD probably slightly reduce pain and improve function (moderate-certainty evidence).
- Low-THC and CBD-only products did not appear to help.
- THC products came with a notably higher risk of dizziness, sedation, and nausea.
"Slightly" is the operative word. These are measurable but small changes, studied over months, not years.
One notable study found the lower dose worked as well as the higher one
A frequently cited 2013 trial in The Journal of Pain gave 39 people with neuropathic pain vaporized cannabis at either 1.29% THC, 3.53% THC, or placebo. About 57% in the low-dose group and 61% in the medium-dose group reported at least a 30% reduction in pain intensity, and the difference between the two doses was not statistically significant. In other words, in that study, more THC did not buy more relief.
It is a small, older study using a vaporizer rather than combustion, so it should not be stretched too far. But it echoes a pattern that shows up across cannabis research: effects tend to plateau, while side effects keep climbing with dose.
What physicians currently advise
This part matters, and we would rather you hear it from us.
In April 2025, the American College of Physicians issued best practice advice on cannabis for chronic noncancer pain. It concluded that evidence of benefit is limited, that cannabis should not be a first-line treatment, and, specifically, that clinicians should advise patients against using inhaled cannabis to manage chronic noncancer pain. It also advised against any cannabis use for pain during pregnancy, breastfeeding, or when trying to conceive.
That guidance covers smoking, which is how The DART is used. We are not going to spin around it. If you are dealing with pain, the right starting point is a conversation with a clinician who knows your history, and that conversation should include the risks of inhalation.
Claim check
| What you might hear | What the evidence actually says |
|---|---|
| "Cannabis cures pain." | Large reviews find small, short-term improvements for some people, mostly with neuropathic pain. |
| "More THC means more relief." | At least one controlled trial found a low dose worked about as well as a higher one, while side effects rise with dose. |
| "CBD alone handles pain." | CBD-only and low-THC products did not appear helpful in the major 2025 review. |
| "Doctors are on board with smoking it." | The American College of Physicians advises against inhaled cannabis for chronic noncancer pain. |
Where a measured system fits
Many adults choose to consume flower anyway, for their own reasons and within the law. For them, the research points to one practical takeaway: the amount matters, and consistency beats guesswork. That is the only thing The DART is built to help with.
It starts in the canister. Our herb canisters store pre-ground flower in an airtight, smell-proof metal container you can take anywhere: the Standard Canister holds 3.5 grams, the Premium Canister and Model III Canister hold 6 grams, and the XL Canister holds 12. Your DART nests inside, and you load it by dipping the chamber into the flower, twisting, and lifting.
The chamber sets the amount. Each DART holds a fixed volume of ground flower, so every session is the same size unless you deliberately change it:
- DART MD: 0.15 grams, the smallest and most conservative load.
- DART Pro: 0.25 grams, with an integrated filter and mesh screen for a cooler draw. Also available as the DART Pro Titanium.
- DART Plus: 0.30 grams, the largest measured load.
We offer varying capacities because people want different, specific effects, and a fixed chamber is how you keep one variable steady while you and your clinician pay attention to how you respond. It does not make cannabis safer or more effective for pain. It simply replaces a guess with a known amount.
If you are considering cannabis for pain
These are not instructions, just the questions the research suggests are worth asking a healthcare professional:
- Is cannabis appropriate for my type of pain, given that most evidence involves neuropathic pain?
- How do the risks of inhalation compare with non-inhaled options for me?
- Could it interact with my other medications or conditions?
- If I do use it, how should I track the amount and my response over time?
Pain is personal, and the evidence is still catching up. What we can offer is honesty about what is known and a tool that keeps the amount consistent for adults who choose to use it.
This article summarizes published research and professional guidance for general information only. It is not medical advice. The DART Company does not advocate the use of cannabis to diagnose, treat, cure, or prevent any condition, including pain, and our products are not medical devices. Consult a qualified healthcare professional before using cannabis for any health purpose. Chamber and canister capacities are physical specifications. Cannabis laws vary by location; use only where legal and only if you are of legal age.
Sources
- Boehnke KF, et al. Qualifying Conditions of Medical Cannabis License Holders in the United States. Health Affairs (2019). healthaffairs.org
- Bonar EE, et al. How Older Adults Use, Think About, and Discuss Cannabis. University of Michigan National Poll on Healthy Aging (2024). ihpi.umich.edu
- Yang K, Leas E, et al. Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among US Adults. American Journal of Preventive Medicine (2026). today.ucsd.edu
- Cannabis-Based Products for Chronic Pain: An Updated Systematic Review. Annals of Internal Medicine (2025). acpjournals.org
- Wilsey B, et al. Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. The Journal of Pain (2013). jpain.org
- Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice From the American College of Physicians. Annals of Internal Medicine (2025). acpjournals.org
